Its purpose is to prime the body and minimize early gastrointestinal side effects before escalation begins
These SCFAs directly stimulate L-cells in the intestine to release GLP-1
How soon will I start seeing results? Many patients notice changes within the first few week, better appetite control, improved energy, and reduced cravings
For that reason, any decision to pause or stop GLP-1 therapy should always be made in consultation with a qualified healthcare provider who can document the plan, adjust dosing, and help protect continued coverage
Conclusions and future directions In conclusion, we report that anticoagulant, sample processing, and sample storage methods significantly affect levels of GSH within plasma samples and that these methodological differences impact post-processing summary reporting
The other 75% is dependent on environmental factors